Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
合伙人律师
Pirozzolo, Jack W.
合伙人律师

Related Blogs

Capabilities

Suggested News & Insights

$14.1 Million FCA Settlement Underscores Medicare Advantage Coding ScrutinyAugust 6, 2026
Original Source
New York Ethics Opinion Addresses Ethical Limits on Attorney Participation in Whistleblower InvestigationsJuly 30, 2026
Original Source
Laboratory, Owners, and Investors Settle COVID-19 Testing Fraud Allegations for $24 MillionJuly 27, 2026
Original Source
DOJ Releases FOCUS Questionnaire to Assist in Evaluating Qui Tams Filed by Data MinersJuly 20, 2026
Original Source
June DOJ/SBA FCA Settlement Highlights Continued Focus on Contractor ComplianceJuly 15, 2026
Original Source
Texas Supreme Court Imposes Materiality Requirement on Texas Healthcare Fraud Omissions ClaimsJuly 7, 2026
Original Source